Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 19:20
Vera Therapeutics Cash from Operations (Quarterly): -33.83M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -33.83M |
| December 31, 2023 | -25.14M |
| September 30, 2023 | -22.97M |
| June 30, 2023 | -17.77M |
| March 31, 2023 | -26.29M |
| December 31, 2022 | -21.16M |
| September 30, 2022 | -18.42M |
| June 30, 2022 | -19.03M |
| March 31, 2022 | -8.981M |
| Date | Value |
|---|---|
| December 31, 2021 | -6.438M |
| September 30, 2021 | -5.484M |
| June 30, 2021 | -7.665M |
| March 31, 2021 | -4.121M |
| December 31, 2020 | -27.38M |
| September 30, 2020 | -2.447M |
| June 30, 2020 | -2.675M |
| March 31, 2020 | -2.305M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-33.83M
Minimum
Mar 2024
-2.305M
Maximum
Mar 2020
-14.83M
Average
-17.77M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 1.307B |
| Alpine Immune Sciences Inc | -27.69M |
| Fate Therapeutics Inc | -33.35M |
| Mersana Therapeutics Inc | -32.66M |
| Equillium Inc | -8.80M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -219.29M |
| Cash from Financing (Quarterly) | 276.54M |
| Free Cash Flow | -99.72M |
| Free Cash Flow Per Share (Quarterly) | -0.6637 |
| Free Cash Flow Yield | -5.24% |